BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN), a small molecule drug discovery and development company, announced today that it has appointed three executives to positions as vice president: Arunee Changchit, Vice President, Drug Metabolism and Pharmacokinetics; Jeffrey Dill, Vice President, General Counsel and Secretary; and Ricardo Ochoa, Vice President, Preclinical Safety.
